Akebia buys ADX-097 from Q32 Bio for $10M upfront (total up to $582M milestones); plans Phase 2 trials in 2026

Akebia Therapeutics, Inc.

Upfront $7M paid at closing, additional $3M due in 6 months; development milestones up to $94.5M and commercial milestones up to $487.5M, plus tiered royalties from low single to mid-teen %.
AKB-097 is a tissue-targeted C3d-Factor H fusion protein complement inhibitor; Phase 2 basket trial in multiple rare kidney diseases planned to start treating subjects in 2026.
Praliciguat (sGC stimulator) Phase 2 trial initiated in FSGS; additional rare podocytopathy indications planned.
Existing cash resources plus cash from operations expected to fund current operating plan for at least 2 years.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Akebia Therapeutics, Inc. entered into Asset Purchase Agreement with Q32 Bio Inc. and Q32 Bio Operations Inc. (together, "Q32") valued at $7.0 million (effective 2025-11-28).

Action: entry
Agreement: asset purchase
Counterparty: Q32 Bio Inc. and Q32 Bio Operations Inc. (together, "Q32")
Value: $7.0 million
Effective: 2025-11-28

Exact text from the filing

On November 28, 2025 (the “Closing Date”), Akebia Therapeutics, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”) with Q32 Bio Inc. and Q32 Bio Operations Inc. (together, “Q32”)

View on SEC.gov

Browse all material agreements →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-25-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.